Whitepaper: Why BioPharma Lifecycle Management?
Posted: 28 January 2021 | IDBS | No comments yet
In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.
The biopharmaceutical industry has big ambitions to accelerate the move towards industry 4.0. In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation. We conclude by exploring the role effective BioPharmaceutical Lifecycle Management BPLM platforms will play in accelerating time to market for vaccines and therapies.
Related content from this organisation
- An integrated vaccination approach to neurodegeneration
- ebook: High-Throughput Data Management in process development
- Whitepaper: Buying a digital informatics system for your R&D?
- Making cell culture models more physiologically relevant
- ebook: Why you need to digitally transform your R&D organisation
Related topics
Analytical techniques, Antibodies, Assays, Bioengineering, Biomarkers, Biopharmaceuticals, Cell culture, Disease research, Genome editing, Hit-to-Lead, Imaging, Immunology, Informatics, Lab Automation, Personalised Medicine, Screening, Stem Cells
Related organisations
IDBS
